David Engelmann

3.7k total citations
22 papers, 1.1k citations indexed

About

David Engelmann is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, David Engelmann has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 11 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in David Engelmann's work include Cancer-related Molecular Pathways (8 papers), Epigenetics and DNA Methylation (6 papers) and DNA Repair Mechanisms (3 papers). David Engelmann is often cited by papers focused on Cancer-related Molecular Pathways (8 papers), Epigenetics and DNA Methylation (6 papers) and DNA Repair Mechanisms (3 papers). David Engelmann collaborates with scholars based in Germany, South Africa and United States. David Engelmann's co-authors include Brigitte M. Pützer, Vijay Alla, Alf Spitschak, Ulf Schmitz, Bhavani S. Kowtharapu, Claudia Meier, Olaf Wolkenhauer, Stephan Emmrich, Jens Pahnke and Stephan Marquardt and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and JNCI Journal of the National Cancer Institute.

In The Last Decade

David Engelmann

22 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Engelmann Germany 19 780 388 362 104 93 22 1.1k
Alice Faversani Italy 15 644 0.8× 262 0.7× 419 1.2× 113 1.1× 61 0.7× 20 1.0k
Zuowei Zhao China 17 512 0.7× 430 1.1× 292 0.8× 134 1.3× 96 1.0× 55 923
Ajish George United States 10 671 0.9× 389 1.0× 312 0.9× 66 0.6× 156 1.7× 16 1.1k
Gaynor Davies United Kingdom 19 576 0.7× 351 0.9× 255 0.7× 99 1.0× 87 0.9× 22 1.0k
Peter Čamaj Germany 16 507 0.7× 355 0.9× 279 0.8× 78 0.8× 81 0.9× 22 788
Nathan Ungerleider United States 20 673 0.9× 313 0.8× 410 1.1× 131 1.3× 170 1.8× 41 1.1k
Yanqing Ding China 18 800 1.0× 296 0.8× 536 1.5× 125 1.2× 63 0.7× 39 1.2k
Nino Keshelava United States 19 914 1.2× 454 1.2× 293 0.8× 120 1.2× 134 1.4× 33 1.4k
Aleksandra M. Michalowski United States 16 819 1.1× 438 1.1× 212 0.6× 123 1.2× 92 1.0× 29 1.2k
Yari Ciani Italy 18 933 1.2× 394 1.0× 482 1.3× 213 2.0× 89 1.0× 27 1.4k

Countries citing papers authored by David Engelmann

Since Specialization
Citations

This map shows the geographic impact of David Engelmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Engelmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Engelmann more than expected).

Fields of papers citing papers by David Engelmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Engelmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Engelmann. The network helps show where David Engelmann may publish in the future.

Co-authorship network of co-authors of David Engelmann

This figure shows the co-authorship network connecting the top 25 collaborators of David Engelmann. A scholar is included among the top collaborators of David Engelmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Engelmann. David Engelmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Logotheti, Stella, Stephan Marquardt, Shailendra K. Gupta, et al.. (2020). LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1. Theranostics. 10(21). 9620–9643. 71 indexed citations
2.
Gupta, Shailendra K., David Engelmann, Alf Spitschak, et al.. (2019). Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers. Theranostics. 9(5). 1490–1509. 16 indexed citations
3.
Logotheti, Stella, Alf Spitschak, Stephan Marquardt, et al.. (2018). DNp73-induced degradation of tyrosinase links depigmentation with EMT-driven melanoma progression. Cancer Letters. 442. 299–309. 22 indexed citations
4.
Spitschak, Alf, Claudia Meier, Bhavani S. Kowtharapu, David Engelmann, & Brigitte M. Pützer. (2017). MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit. Molecular Cancer. 16(1). 24–24. 48 indexed citations
5.
Khan, Faiz M., Stephan Marquardt, Shailendra K. Gupta, et al.. (2017). Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures. Nature Communications. 8(1). 198–198. 65 indexed citations
6.
Wang, Yajie, Vijay Alla, Shailendra K. Gupta, et al.. (2015). Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures. Nucleic Acids Research. 44(1). 117–133. 32 indexed citations
7.
Engelmann, David, Claudia Meier, Vijay Alla, & Brigitte M. Pützer. (2014). A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression. Oncogene. 34(33). 4287–4299. 45 indexed citations
8.
Engelmann, David & Brigitte M. Pützer. (2014). Emerging from the shade of p53 mutants: N-terminally truncated variants of the p53 family in EMT signaling and cancer progression. Science Signaling. 7(345). re9–re9. 27 indexed citations
9.
Vera, Julio, Ulf Schmitz, Xin Lai, et al.. (2013). Kinetic Modeling–Based Detection of Genetic Signatures That Provide Chemoresistance via the E2F1-p73/DNp73-miR-205 Network. Cancer Research. 73(12). 3511–3524. 43 indexed citations
10.
Khan, Faiz M., Ulf Schmitz, Svetoslav Nikolov, et al.. (2013). Hybrid modeling of the crosstalk between signaling and transcriptional networks using ordinary differential equations and multi-valued logic. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1844(1). 289–298. 19 indexed citations
11.
Engelmann, David, Vijay Alla, Alf Spitschak, et al.. (2013). E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B. Journal of Molecular Cell Biology. 5(6). 391–403. 57 indexed citations
12.
Alla, Vijay, Claudia Meier, Alf Spitschak, et al.. (2013). DNp73 Exerts Function in Metastasis Initiation by Disconnecting the Inhibitory Role of EPLIN on IGF1R-AKT/STAT3 Signaling. Cancer Cell. 24(4). 512–527. 81 indexed citations
13.
Pützer, Brigitte M. & David Engelmann. (2012). E2F1 apoptosis counterattacked: evil strikes back. Trends in Molecular Medicine. 19(2). 89–98. 74 indexed citations
14.
Alla, Vijay, Bhavani S. Kowtharapu, David Engelmann, et al.. (2012). E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle. 11(16). 3067–3078. 81 indexed citations
15.
Engelmann, David & Brigitte M. Pützer. (2012). The Dark Side of E2F1: In Transit beyond Apoptosis. Cancer Research. 72(3). 571–575. 125 indexed citations
16.
Engelmann, David & Brigitte M. Pützer. (2010). Translating DNA damage into cancer cell death—A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance. Drug Resistance Updates. 13(4-5). 119–131. 54 indexed citations
17.
Alla, Vijay, David Engelmann, Jens Pahnke, et al.. (2009). E2F1 in Melanoma Progression and Metastasis. JNCI Journal of the National Cancer Institute. 102(2). 127–133. 103 indexed citations
18.
Engelmann, David, et al.. (2009). Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death. Cellular and Molecular Life Sciences. 67(6). 931–948. 20 indexed citations
19.
20.
Engelmann, David, et al.. (2006). Direct stimulatory effects of the TLR2/6 ligand bacterial lipopeptide MALP-2 on neutrophil granulocytes. Medical Microbiology and Immunology. 196(2). 61–71. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alice Faversani Breakdown of academic impact, for papers by Zuowei Zhao Breakdown of academic impact, for papers by Ajish George Breakdown of academic impact, for papers by Gaynor Davies Breakdown of academic impact, for papers by Peter Čamaj Breakdown of academic impact, for papers by Nathan Ungerleider Breakdown of academic impact, for papers by Yanqing Ding Breakdown of academic impact, for papers by Nino Keshelava Breakdown of academic impact, for papers by Aleksandra M. Michalowski Breakdown of academic impact, for papers by Yari Ciani
Rankless by CCL
2026